Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Equity Ratio (2017 - 2025)

Aclaris Therapeutics has reported Equity Ratio over the past 9 years, most recently at 0.64 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.64 for Q4 2025, down 9.01% from a year ago — trailing twelve months through Dec 2025 was 0.64 (down 9.01% YoY), and the annual figure for FY2025 was 0.64, down 9.01%.
  • Equity Ratio for Q4 2025 was 0.64 at Aclaris Therapeutics, down from 0.68 in the prior quarter.
  • Over the last five years, Equity Ratio for ACRS hit a ceiling of 0.85 in Q2 2022 and a floor of 0.64 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.77 (2022), compared with a mean of 0.76.
  • Biggest five-year swings in Equity Ratio: surged 47.69% in 2021 and later decreased 16.17% in 2025.
  • Aclaris Therapeutics' Equity Ratio stood at 0.79 in 2021, then decreased by 1.19% to 0.78 in 2022, then rose by 2.58% to 0.8 in 2023, then fell by 11.33% to 0.71 in 2024, then dropped by 9.01% to 0.64 in 2025.
  • The last three reported values for Equity Ratio were 0.64 (Q4 2025), 0.68 (Q3 2025), and 0.7 (Q2 2025) per Business Quant data.